Stay updated on Pembrolizumab and Lenvatinib in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Lenvatinib in Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab and Lenvatinib in Melanoma Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedAdded a new publication citation for LEAP-003 results (Ann Oncol. 2025) in Publications and updated the existing entry to Revision: v3.3.2 (from v3.2.0).SummaryDifference0.4%

- Check19 days agoChange Detected- Removed the government funding notice from the page. The notice previously warned that information may not be up to date due to funding lapses and directed users to opm.gov for updates.SummaryDifference0.2%

- Check34 days agoChange DetectedAdded a Publications entry with a 2025 LEAP-003 study article citation and a Study Results section, and removed two older update dates (2025-10-17 and 2025-10-01).SummaryDifference0.4%

- Check62 days agoChange DetectedAdded a government operating status notice and updated version to v3.2.0; removed the previous v3.1.0 tag.SummaryDifference2%

- Check69 days agoChange DetectedAppended version label (v3.1.0) and removal of multiple drug-safety related sections, indicating content consolidation and reorganization rather than new substantive content.SummaryDifference0.2%

- Check84 days agoChange DetectedThe revision label updated from v3.0.1 to v3.0.2, indicating a minor release. The Back to Top element was removed, with no other substantive content changes evident.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab and Lenvatinib in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Lenvatinib in Melanoma Clinical Trial page.